文献速递瓣膜病与结构性心脏病

REFLECT I试验:TriGuard HDH脑栓塞保护装置在TAVR中的随机评价

A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial.
PubMed 文献 · Eur Heart J · 2021-01-01

REFLECT I为前瞻性、多中心、单盲、2:1随机对照试验,评估TriGuard HDH脑栓塞偏转装置在经导管主动脉瓣置换术(TAVR)中的安全性和有效性。主要安全终点达到预设性能目标(21.8% vs. 35%,P<0.0001),但主要分级疗效终点未达到(平均疗效评分-5.3±99.8 vs. 11.8±96.4,P=0.31)。结论认为该装置安全性可接受但未显示优于无保护TAVR的疗效。

要点

  • TriGuard HDH在TAVR中30天早期安全终点达标,但未达主要疗效复合终点。
  • 隐匿性中枢神经系统损伤数值上低于对照,但差异未达统计学显著。
  • 主要疗效终点采用Finkelstein-Schoenfeld法比较分级复合终点。

核心结论

  • TriGuard HDH脑栓塞保护装置在TAVR中安全性可接受,但未达到预设的主要疗效终点。

研究设计与样本

  • 前瞻性、多中心、单盲、2:1随机对照试验,计划入组最多375例患者(含最多90例滚入期患者),实际入组258例(68.8%),其中滚入期54例、随机204例。

主要发现

  • 主要安全终点(VARC-2定义的30天早期安全)为21.8%,低于预设性能目标35%(P<0.0001)。
  • 主要分级疗效终点未达到:平均疗效评分TriGuard组-5.3±99.8,对照组11.8±96.4(P=0.31)。
  • 隐匿性中枢神经系统损伤住院期间发生率TriGuard组46.1% vs. 对照组60.3%(P=0.0698),5天时61.7% vs. 76.2%(P=0.054)。

关键数值与推荐

  • 主要安全终点与预设性能目标35%比较,实际发生率21.8%,P<0.0001。
  • 主要疗效终点为分级复合终点,包括30天全因死亡或任何卒中、2-5天NIHSS恶化或30天蒙特利尔认知评估恶化、2-5天弥散加权磁共振成像检测的脑缺血病灶总体积。
  • 采用Finkelstein-Schoenfeld法比较累积评分,TriGuard组平均疗效评分-5.3±99.8,对照组11.8±96.4,P=0.31。

临床怎么用

  • 该装置在TAVR中显示出可接受的安全性,但未证实可改善分级复合疗效终点。
  • 隐匿性中枢神经系统损伤的数值差异需进一步研究验证。

局限性

  • 实际入组258例,低于计划的375例(68.8%)。
  • 主要疗效终点未达到,研究可能不足以检测某些终点的差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The REFLECT I trial investigated the safety and effectiveness of the TriGuard™ HDH (TG) cerebral embolic deflection device in patients undergoing transcatheter aortic valve replacement (TAVR). METHODS AND RESULTS: This prospective, multicentre, single-blind, 2:1 randomized (TG vs. no TG) study aimed to enrol up to 375 patients, including up to 90 roll-in patients. The primary combined safety endpoint (VARC-2 defined early safety) at 30 days was compared with a performance goal. The primary efficacy endpoint was a hierarchical composite of (i) all-cause mortality or any stroke at 30 days, (ii) National Institutes of Health Stroke Scale (NIHSS) worsening at 2-5 days or Montreal Cognitive Assessment worsening at 30 days, and (iii) total volume of cerebral ischaemic lesions detected by diffusion-weighted magnetic resonance imaging at 2-5 days. Cumulative scores were compared between treatment groups using the Finkelstein-Schoenfeld method. A total of 258 of the planned, 375 patients (68.8%) were enrolled (54 roll-in and 204 randomized). The primary safety outcome was met compared with the performance goal (21.8% vs. 35%, P < 0.0001). The primary hierarchical efficacy endpoint was not met (mean efficacy score, higher is better: -5.3 ± 99.8 TG vs. 11.8 ± 96.4 control, P = 0.31). Covert central nervous system injury was numerically lower with TG both in-hospital (46.1% vs. 60.3%, P = 0.0698) and at 5 days (61.7 vs. 76.2%, P = 0.054) compared with controls. CONCLUSION: REFLECT I demonstrated that TG cerebral protection during TAVR was safe in comparison with historical TAVR data but did not meet the predefined effectiveness endpoint compared with unprotected TAVR controls.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lansky AJ, Makkar R, Nazif T, et al. A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. Eur Heart J. 2021. PMID: 34000004. doi:10.1093/eurheartj/ehab213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。